AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00390156
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Current dose 50 mg
Trial: NCT03945357
Drug: Gemcitabine/ clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of saline solution rinse vs antibiotic rinse
Trial: NCT01648023
Drug: Gem-Cis or Gem-Carbo
RxNorm normalized name: Carbo animalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00618423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
Trial: NCT03616496
Drug: Neuraceq PET/CT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
Trial: NCT03945357
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of saline solution rinse vs antibiotic rinse
Trial: NCT01407679
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Trial: NCT00171678
Drug: Diclofenac Topical Sodium Gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02637128
Drug: artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
Trial: NCT02067715
Drug: Tooth bleaching
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The bleaching agent will be used in a single-application of 45 minutes.
Trial: NCT00442585
Drug: S(+)-ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00190307
Drug: aspirin 75 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 75 mg/day
Trial: NCT03976362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to olaparib, tablets
Trial: NCT03349177
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/m2
Trial: NCT03349177
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/m2(FEC), 600mg/m2(EC-T and TC)
Trial: NCT00606450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo taken either 1 or 2 times per day for 12 weeks
Trial: NCT02650336
Drug: contrast
RxNorm normalized name: CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
Trial: NCT01116141
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg MTX weekly
Trial: NCT01116141
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg folic acid daily
Trial: NCT00446589
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv 1mg ibandronate monthly for one year
Trial: NCT00058474
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 oral daily 5 days a week on days of planned RT
Trial: NCT00058474
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 225 mg/m2 IV daily continuous infusion
Trial: NCT02075970
Drug: Biotinylated Red Blood Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
Trial: NCT03583866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of Placebo
Trial: NCT01037881
Drug: LEO 29102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT01037881
Drug: Elidel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison
Trial: NCT00764751
Drug: LEO 19123 Cream (calcipotriol plus LEO 80122)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT00764751
Drug: Dovonex® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00920829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05494775
Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Trial: NCT03815825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching solution, administered subcutaneously every 4 weeks
Trial: NCT02169583
Drug: GSK1325756 Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
Trial: NCT02169583
Drug: GSK1325756 Solution Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
Trial: NCT02169583
Drug: GSK1325756 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
Trial: NCT02169583
Drug: GSK1325756 Tablet Matching Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A white film coated tablet matching GSK1325756 tablet, to be administered orally.
Trial: NCT02734615
Drug: LSZ102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSZ102
Trial: NCT02734615
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011
Trial: NCT02734615
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719
Trial: NCT04192266
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
Trial: NCT04192266
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
Trial: NCT02588937
Drug: EntecaBell ODT. 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02588937
Drug: Baraclude Tab. 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04014023
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 tablets
Trial: NCT04014023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 placebo-matching tablets
Trial: NCT03004222
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00638807
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Trial: NCT02777736
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: i.v. or intrathecal CNS prophylaxis
Trial: NCT01796431
Drug: Eviplera®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01507831
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Trial: NCT01507831
Drug: Lipid-Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Trial: NCT01664494
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
Trial: NCT01559974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to 45'000 units of Cholecalciferol per month for 3 months
Trial: NCT00698932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, once daily for 24 weeks
Trial: NCT04513340
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
RxNorm normalized name: Carbidopa and Levodopa Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
Trial: NCT02233868
Drug: neuroinflammation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
Trial: NCT03457025
Drug: Oral Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
Trial: NCT03457025
Drug: Oral antivirals
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acyclovir 400mg: one pill 4 times daily for 7 days
Trial: NCT02616744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 oral capsule of placebo per month
Trial: NCT02236156
Drug: 1% SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
Trial: NCT01218633
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infused at 30ml/hour
Trial: NCT01218633
Drug: GLP-1-9,36 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infused @ 1.2pmol/kg/min
Trial: NCT03573700
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04233164
Drug: Solu-Medrol 1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
Trial: NCT02236156
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Trial: NCT01218633
Drug: Exendin-9,39 at low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infused at 30pmol/kg/min
Trial: NCT01218633
Drug: Exendin-9,39 at high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infused @ 300pmol/kg/min
Trial: NCT00630851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets orally once daily for 6 months
Trial: NCT02856867
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02856867
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02856867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00879970
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
Trial: NCT00928798
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
Trial: NCT03663569
Drug: Spiolto® Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT02226939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01076166
Drug: clarithromycin (Klacid) granules for oral suspension
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin (Klacid) Granules for Oral Suspension
Trial: NCT00821457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for solution for injection
Trial: NCT00384358
Drug: rhBMP-2/CPM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one time injection of 3-5 mL test article at time of internal fracture fixation
Trial: NCT00002571
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 490 mg/m2 IV Q 21 days x 6 cycles
Trial: NCT00002571
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 19 mg/m2 IV Q 21 days x 6 cycles
Trial: NCT00002571
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
Trial: NCT00002571
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m2 IV, Q 21 days x 6 cycles.
Trial: NCT01918709
Drug: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Trial: NCT01918709
Drug: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Trial: NCT01918709
Drug: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Trial: NCT01918709
Drug: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Trial: NCT01918709
Drug: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Trial: NCT01918709
Drug: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Trial: NCT00707915
Drug: Drug: Benzodiazepine (listed out below)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks.
Trial: NCT00002576
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002576
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00252187
Drug: B-type Natriuretic Peptide (BNP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
Trial: NCT00002576
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00290212
Drug: Natto capsules (food suppl.) cont. 360 microg. vit K2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00290212
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02568995
Drug: ropivacaine + ketorolac + adrenaline
RxNorm normalized name: CLONIDINE/KETOROLAC/ROPIVACAINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of drugs injected locally for postoperative pain management
Trial: NCT00891878
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT04554693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
Trial: NCT02546635
Drug: AX-024.HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AX-024.HCl will be administered as per the protocol defined frequency and dose level
Trial: NCT00880373
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
Trial: NCT00880373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo three times daily for 4 days
Trial: NCT01097798
Drug: Aliviador
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Trial: NCT01097798
Drug: Gelol
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [GELOX 100]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Trial: NCT06180954
Drug: [14C]-LOXO-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06180954
Drug: [14C]-LOXO-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02028871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03260439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
Trial: NCT00743964
Drug: Cisplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
Trial: NCT04231318
Drug: Cingal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of Cingal into the knee.
Trial: NCT04231318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection Placebo (0.9% Saline) into the knee.
Trial: NCT00989573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of placebo once-daily for 8 weeks
Trial: NCT00817583
Drug: docetaxel, cisplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly
Trial: NCT00586196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated cornstarch One capsule daily for 30 days
Trial: NCT03953118
Drug: Azithromycin Oral Product
RxNorm normalized name: azithromycin Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azithromycin dosed at 1 gram per week for 3 weeks
Trial: NCT03953118
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet
Trial: NCT00792831
Drug: ITF2357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histone-Deacetylase Inhibitor
Trial: NCT02280473
Drug: Refresh Optive® Gel Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.